

**KREBS BIOCHEMICALS & INDUSTRIES LIMITED**


CIN: L24110AP1991PLC103912

Registered Office: Kothapalli Village, Kasimkota Mandal, Ankapalli, Visakhapatnam, Andhra Pradesh - 531 031

Corporate Office: 8-2-577/B, Plot No:34, 3rd Floor, Maas Heights, Road No:8, Banjara Hills, Hyderabad - 500 034

**STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER / PERIOD ENDED JUNE 30, 2018**

(Rs. In Lacs)

| (Rs. In Lacs)     |   |  |                         |                            |                         |
|-------------------|---|--|-------------------------|----------------------------|-------------------------|
| Sl.No             | Particulars   | Quarter Ended  |                         |                            | Year Ended              |
|                   |   | 30.06.2018<br>(Un Audited)   | 31.03.2018<br>(Audited) | 30.06.2017<br>(Un Audited) | 31.03.2018<br>(Audited) |
|                   | <b>PART - 1</b>   |  |                         |                            |                         |
| 1                 | Revenue from Operations   |  |                         |                            |                         |
|                   | a) Net Sales/Income from Operations   | 654.74   | 622.00                  | 76.38                      | 2538.24                 |
|                   | b) Other Operating Income   | 239.93   | 398.55                  | 39.00                      | 839.67                  |
| 2                 | Other Income  | 3.00   | 15.43                   | 4.03                       | 20.61                   |
| 3                 | <b>Total Income (1+2)</b>   | <b>897.67</b>  | <b>1,035.98</b>         | <b>119.41</b>              | <b>3,398.52</b>         |
| 4                 | Expenses  |  |                         |                            |                         |
|                   | a) Cost of Materials Consumed   | 114.28   | 534.07                  | 30.41                      | 1712.36                 |
|                   | b) Changes in Inventories of Finished Goods, Work-In-Progress   | 339.21   | (171.30)                | 54.08                      | -441.83                 |
|                   | c) Employee Benefits Expenses   | 340.03   | 516.28                  | 149.04                     | 1148.53                 |
|                   | d) Finance Costs  | 142.40   | 142.14                  | 108.19                     | 516.52                  |
|                   | e) Depreciation and Amortisation Expenses   | 107.37   | 109.40                  | 101.86                     | 414.97                  |
|                   | f) Other Manufacturing Expenses   | 304.49   | 519.21                  | 172.96                     | 1320.57                 |
|                   | g) Other Expenses   | 76.39  | 103.89                  | 77.27                      | 388.46                  |
|                   | <b>Total Expenses (4)</b>   | <b>1,424.17</b>  | <b>1,753.69</b>         | <b>693.81</b>              | <b>5,059.58</b>         |
| 5                 | <b>Profit / (Loss) before exceptional items and tax (3±4)</b>   | <b>(526.50)</b>  | <b>(717.70)</b>         | <b>(574.39)</b>            | <b>(1,661.06)</b>       |
| 6                 | Exceptional Items:  |  |                         |                            |                         |
|                   | a) Depletion in Value of Inventory  | -  | -                       | (22.52)                    | (95.35)                 |
|                   | b) Amounts Written Back   | -  | (0.89)                  | -                          | (0.89)                  |
|                   | c) Prior Period Income/(Expenditure)  | -  | (43.59)                 | 3.56                       | (40.03)                 |
|                   | d) Profit on sale of Fixed Assets   | -  | 14.83                   | -                          | 14.83                   |
| 7                 | <b>Profit / (Loss) before Tax (5±6)</b>   | <b>(526.50)</b>  | <b>(747.35)</b>         | <b>(593.36)</b>            | <b>(1,782.49)</b>       |
| 8                 | Tax Expense   |  |                         |                            |                         |
|                   | a) Current Tax  | -  | -                       | -                          | -                       |
|                   | b) Deferred Tax   | -  | -                       | -                          | -                       |
| 9                 | <b>Profit / (Loss) for the period (7±8)</b>   | <b>(526.50)</b>  | <b>(747.35)</b>         | <b>(593.36)</b>            | <b>(1,782.49)</b>       |
| 10                | Other Comprehensive Income  | (26.59)  | (76.37)                 | (21.20)                    | (143.12)                |
| 11                | <b>Total Comprehensive Income for the period(9±10)<br/>(Comprising Profit / (Loss) and Other Comprehensive Income for the period)</b>   | <b>(553.09)</b>  | <b>(823.71)</b>         | <b>(614.56)</b>            | <b>(1,925.61)</b>       |
| 12                | Paid-up equity share capital (Face value of Rs 10/- each)   | 1,374.43   | 1,374.43                | 1,374.43                   | 1,374.43                |
| 13                | Other Equity  |  |                         |                            | (3,152.35)              |
| 14                | <b>Earning Per Share (of Rs.10/- each) (not Annualised):</b>  |  |                         |                            |                         |
|                   | a) Basic  | (4.02)   | (5.99)                  | (4.47)                     | (14.01)                 |
|                   | b) Diluted  | (4.02)   | (5.99)                  | (4.47)                     | (14.01)                 |
|                   | See accompanying notes to the Financial results   |  |                         |                            |                         |
| 1                 | The above results have been reviewed by the Audit Committee at its meeting held on July 30, 2018 and approved by the Board of Directors of the Company at its meeting held on July 30, 2018. The results are subject to limited review by statutory auditors. |  |                         |                            |                         |
| 2                 | The Company is operating in one segment only hence no segment results have been disclosed.  |  |                         |                            |                         |
| 3                 | Effective from July 01, 2017, Revenue from operations is presented net of taxes and duties, on implementation of Goods and Services Tax Act. Hence the results of the quarter ended June 30, 2018 and June 30, 2017 are not comparable.                       |  |                         |                            |                         |
| 4                 | The results for the quarter ended 31.03.2018 are the balancing figures between the audited figures in respect of the full financial year and published year to date figures upto third quarter of the relevant financial year.                                |  |                         |                            |                         |
| 5                 | The above financial results are prepared in accordance with IND AS notified under the Company (Indian Accounting Standards) Rules, 2015.  |  |                         |                            |                         |
| Place : Hyderabad |   | <br>Avinash Ravi<br>Managing Director<br>DIN*01616052 |                         |                            |                         |
| Date : 30.07.2018 |   |  |                         |                            |                         |



## PAVULURI & Co.

CHARTERED ACCOUNTANTS

Plot No.48, Flat No.301,  
Sucasa, Phase - I, Kavuri Hills,  
Hyderabad - 500 033.  
Ph : 040-2970 2638 / 2639 / 2640  
Email : pavuluriandco@gmail.com

### Limited Review Report

**Review Report to  
The Board of Directors,  
KREBS BIO-CHEMICALS & INDUSTRIES LIMITED**

1. We have reviewed the accompanying statement of unaudited standalone financial results of **M/s. KREBS BIO-CHEMICALS & INDUSTRIES LIMITED** ("the Company") for the quarter ended June 30, 2018 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Regulations"), read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 ("the Circular").
2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015 and the Circular, which is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad  
Date: 30.07.2018

For PAVULURI & Co.  
Chartered Accountants  
Firm Regn. No: 012194S

*N. Rajesh*  
(CA. N. RAJESH)  
PARTNER  
M.No: 223169

